{"title":"Jazz和Concert合作开发氘修饰版Xyrem®","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I3.1908","DOIUrl":null,"url":null,"abstract":"Jazz Pharmaceuticals has licensed exclusive worldwide rights to develop and commercialise Concert Pharmaceuticals’ deuterium-modified analogues of sodium oxybate (D-SXB), including its lead compound C-10323. In doing so, the company is looking to develop a follow-on version of its key commercial asset Xyrem® (sodium oxybate), which is indicated for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients. Preclinical data suggest that selective deuterium incorporation can stabilise sodium oxybate in vivo, which could provide for an improved dosing schedule. An IND application for C-10323 is planned for later in 2013.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Jazz and Concert Collaborate to Develop Deuterium-Modified Version of Xyrem®\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I3.1908\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Jazz Pharmaceuticals has licensed exclusive worldwide rights to develop and commercialise Concert Pharmaceuticals’ deuterium-modified analogues of sodium oxybate (D-SXB), including its lead compound C-10323. In doing so, the company is looking to develop a follow-on version of its key commercial asset Xyrem® (sodium oxybate), which is indicated for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients. Preclinical data suggest that selective deuterium incorporation can stabilise sodium oxybate in vivo, which could provide for an improved dosing schedule. An IND application for C-10323 is planned for later in 2013.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I3.1908\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I3.1908","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Jazz and Concert Collaborate to Develop Deuterium-Modified Version of Xyrem®
Jazz Pharmaceuticals has licensed exclusive worldwide rights to develop and commercialise Concert Pharmaceuticals’ deuterium-modified analogues of sodium oxybate (D-SXB), including its lead compound C-10323. In doing so, the company is looking to develop a follow-on version of its key commercial asset Xyrem® (sodium oxybate), which is indicated for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients. Preclinical data suggest that selective deuterium incorporation can stabilise sodium oxybate in vivo, which could provide for an improved dosing schedule. An IND application for C-10323 is planned for later in 2013.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
